Takeda expands vaccine production access; CFDA rallies troops on reforms;

> Takeda Pharmaceutical announced expanded commercialization and technology access rights to Nanotherapeutics' Vero cell technology platform for vaccine production. The platform was acquired from Baxalta, formerly Baxter International's ($BAX) BioScience division, and will be used in the development of pandemic and seasonal influenza vaccines for the Japanese market. Release

> China's top health care officials rallied the troops in Shanghai this week in the "battle" to implement the State Council's push to reform drug approvals in a meeting that included China Food and Drug Administration Minister Bi Jingquan, the CFDA said in a release. "The meeting urged all localities to earnestly carry out the current drug safety supervision," a rough translated version of the release said, adding that the attendees were told to "always focus on risk" and be willing to "identify problems." Release (Chinese language)

> Japan's Denki Kagaku Kogyo plans to earn 50% of group operating profit from its division that includes medical products by March 2018 spurred byoverseas sales of a profitable cholesterol reagent set for release next year, Nikkei Asian Review said. Report

> China-U.S. focused device firm ECM Medical has bought Greater China rights to a novel spinal fusion device called Interfuse that was developed by Minnesota-based Vertebral Technologies and will work to register the device in-country, according to a press release. Financial terms were not disclosed. Release

> California-based DynoSense raised $9.4 million in a Series A funding round for a cloud-based device that captures 33 health metrics and makes them available to health professionals. Investment included China-focused venture firms. Release

> Lee's Pharmaceutical said it will work to register and market anesthetics ropivacaine and propofol from U.S.-based BioQuiddity in China. Eddingpharm will have rights to the drugs in Greater China. Financial terms were not disclosed. Release

> China's WuXi PharmaTech ($WX) and Lee's Pharmaceutical signed an agreement to name WuXi's Laboratory Testing Division as the exclusive supplier of laboratory services for Lee. Release

> China's Jiangxi Boya Bio-Pharmaceutical bought an 84% stake in Nanjing Xinbai Pharmaceutical in exchange for stock, and acquired a 28% interest in Guizhou Tianan Pharmaceuticals for cash this week. No financial details were provided for either transaction, but the company said it would raise up to $78 million through a private placement to pay for the deals as well as a new R&D center and development of new coagulation factor products. Release (Chinese language)

> Takeda Pharmaceutical named Katsuaki Kaneko as the new head of Group Internal Audit. Release

> Japan's Ministry of Health, Labor and Welfare (MHLW) and South Korea's Ministry of Food and Drug Safety signed a mutual understanding agreement on regulatory affairs on Aug. 18, a spokesman for MHLW said, that will include working groups on drug and medical device issues. MHLW site

> Singapore's NMT Pharmaceuticals has signed an agreement with U.S.-based CAO Pharmaceutical for global rights to develop and market anti-cancer drug CZ-48, co-developed by the firms, that would secure funding for CAO Pharma to continue to operate and conduct clinical trials in the U.S., including a Phase I clinical study program this year. Release

> The Hebei Food and Drug Administration in China said testing of drug batches in the province in the first half of the year showed a 97.21% pass rate, an increase of 1.3 percentage points, as stepped up GMP efforts take hold. Release (Chinese language)

> China's Sunflower Pharma plans to buy a 55% stake in an unspecified pharma firm for RMB110 million ($17.1 million). Release (Chinese language)

> Germany's Merck KGaA has shut its Bangalore GeNei operation in Bangalore that was bought in 2009 to aid in biological product research efforts, the Economic Times said, citing a company spokesperson at Merck India. The local unit said the operation has been shut since July 31. Report

> India's Aurobindo Pharma wants revenues to cross $3 billion by 2017-18 by expanding its basket with new drugs to treat cancer and hormonal diseases as well as nutraceuticals and OTC products, the Economic Times said, citing the company's annual report. Report

> Japan's Pharmaceutical and Medical Devices Agency (PDMA) is still open to applications to run a pilot plan to test the feasibility of issues associated with electronically-submitted regulatory data. "We initially announced the closing date of the application period for the FY2015 pilot project to be March 31, 2015," PMDA said on its website. "However, considering the current status of applications in each therapeutic area for the FY2015 pilot project, we have decided to extend the closing date of the application period to September 30, 2015." MHLW site